Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.
In vitro "high post-treatment platelet reactivity" (HPPR) measured with light transmittance aggregometry (LTA) and the VerifyNow P2Y(12) assay has been associated with an increased risk of ischemic events after percutaneous coronary intervention (PCI). However, there are many criteria for HPPR according to the methods used for assessment, and correlations among suggested criteria have not been evaluated. To this end, we enrolled 1,058 unselected patients undergoing PCI in real clinical practice, simultaneously assessed platelet measures with LTA (both 5 and 20 μmol/l ADP-induced) and the VerifyNow P2Y(12) assay, and based on previous studies, evaluated the following criteria for HPPR: 5 or 20 μmol/l ADP-induced maximal platelet reactivity (PR(max)) ≥50%; 5 μmol/l ADP-induced late PR (PR(late)) >14%; 20 μmol/l ADP-induced PR(max) ≥62%; and P2Y(12) reaction unit (PRU) ≥240. Receiver-operating characteristics (ROC) curve analysis demonstrated that PRU (cut-off = 241) distinguished between patients with and without 5 μmol/l ADP-induced PR(max) ≥50% (area under curve [AUC] 0.822, sensitivity 83.0%, specificity 66.0%, P < 0.001), and 20 μmol/l ADP-induced PR(max) ≥62% (AUC 0.840, sensitivity 80.7%, specificity 71.4%, P < 0.001), respectively. PRU ≥240 showed a moderate agreement with 5 μmol/l ADP-induced PR(max) ≥50% (κ = 0.438, concordant rate 71.6%, P < 0.001) and 20 μmol/l ADP-induced PR(max) ≥62% (κ = 0.505, concordant rate 75.1%, P < 0.001). Cut-offs matched for 20 μmol/l ADP-induced PR(max) ≥50% (PRU = 195) and 5 μmol/l ADP-induced PR(late) >14 (PRU = 194) also were similar. The presence of significant correlations between the suggested criteria for HPPR has practical implications on the possible use of the VerifyNow P2Y(12) assay for risk stratification in PCI-treated patients.
Kim
In-Suk
IS
Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea.
Jeong
Young-Hoon
YH
Kang
Min-Kyung
MK
Koh
Jin-Sin
JS
Park
Yongwhi
Y
Hwang
Seok-Jae
SJ
Kwak
Choong Hwan
CH
Hwang
Jin-Yong
JY
Kim
Sunjoo
S
D000368:Aged; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008027:Light; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000097:blood*; D010979:Platelet Function Tests / Q000379:methods; D058925:Receptors, Purinergic P2Y12 / Q000097:blood*; D016896:Treatment Outcome
C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058925:Receptors, Purinergic P2Y12
J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16
17418288
Thromb Res. 2007;119(3):277-84
16563469
Eur Heart J. 2008 Dec;29(23):2877-85
18826988
Circulation. 2003 Jun 17;107(23):2908-13
12796140
Circulation. 2009 Jan 20;119(2):237-42
19118249
Eur Heart J. 2008 Apr;29(8):992-1000
18263931
Eur Heart J. 2008 Sep;29(17):2186-7; author reply 2187
18617479
Thromb Haemost. 2006 May;95(5):910-1
16676093
Am Heart J. 2009 Mar;157(3):562.e1-9
19249429
J Thromb Haemost. 2006 Nov;4(11):2516-8
16938130
JAMA. 2010 Feb 24;303(8):754-62
20179285
Ther Drug Monit. 2008 Jun;30(3):372-8
18520610
J Am Coll Cardiol. 2007 Oct 16;50(16):1541-7
17936152
J Am Coll Cardiol. 2008 May 20;51(20):1925-34
18482659
J Thromb Haemost. 2009 May;7(5):897-9
19220726
J Thromb Haemost. 2006 Mar;4(3):542-9
16371119
Circulation. 2007 Feb 13;115(6):708-16
17261652
J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50
17084243
J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7
17572245
J Am Coll Cardiol. 2005 Nov 15;46(10):1820-6
16286165
Nat Rev Drug Discov. 2003 Jan;2(1):15-28
12509756
Am J Cardiol. 2009 Jul 1;104(1):46-51
19576320
Thromb Res. 2007;120(3):323-36
17239428
JAMA. 2002 Nov 20;288(19):2411-20
12435254
Circulation. 2009 Jun 30;119(25):3215-22
19528337
J Am Coll Cardiol. 2007 Nov 6;50(19):1822-34
17980247
Thromb Haemost. 2008 Feb;99(2):409-15
18278193
J Am Coll Cardiol. 2005 Nov 15;46(10):1827-32
16286166
J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33
18804738
J Am Coll Cardiol. 2007 Feb 13;49(6):657-66
17291930
Lancet. 2001 Aug 18;358(9281):527-33
11520521